Abstract:Background: Increased intraocular pressure is a common symptom of glaucoma. In severe circumstances, it may result in loss of eyesight. Glaucoma treatment is difficult due to ocular physiological barriers that prevent medications from reaching the afflicted area. Traditional formulations (eye drops) have a short residence period and are rapidly drained away via the nasolacrimal duct, resulting in increased adverse drug responses and lower efficacy. The usage of nanoparticles such as niosomes could be one potential answer to these problems. While niosomes improve drug penetration, they have little effect on ocular retention of the medication. Contact lenses containing niosomes can assist to overcome this disadvantage. Objective: This study aims to prepare and evaluate Brimonidine niosomes laden contact lenses for the treatment of Glaucoma. Methods: Brimonidine niosomes were prepared using thin film hydration method and evaluated. The contact lenses were soaked in the niosomal formulation at varying intervals (3-10 days). Thereafter, the contact lenses were evaluated for %transmittance, %swelling index, drug quantification and in vitro drug release. The pharmacodynamic studies were conducted to assess the reduction in intraocular pressure (IOP) in albino rabbits. The research compared the results of the reduction in intraocular pressure caused by Brimonidine niosomes laden contact lenses with a marketed preparation of niosomes. Results: Higher concentration of the drug was loaded in contact lenses loaded with Brimonidine niosomes compared to the marketed formulation, by soaking method. The contact lenses exhibited an optimal %transmittance of 98.02 ± 0.36 and %swelling index of 50.35 ± 0.57. Increase in the soaking time up to 7 days led to an increase in the drug concentration in the contact lenses. However, no further increase was observed after the 7th day due to saturation of the contact lenses. Brimonidine niosomes laden contact lenses provided a reduction in intraocular pressure that was similar to the marketed preparation. Further, the contact lenses provided extended release up to 20 h. Conclusion: Brimonidine niosomes laden contact lenses exhibited superior drug loading through the soaking method, displaying optimal %transmittance and %swelling index. Soaking for 7 days increased drug concentration in contact lenses with no further increase due to saturation. These lenses reduced intraocular pressure like the marketed formulation, offering extended release for 20 h.

Sustained release of brimonidine from conjunctival sac insert to reduce intraocular pressure for glaucoma treatment

Sustained Release of Brimonidine from Polydimethylsiloxane-Coating Silicone Rubber Implant to Reduce Intraocular Pressure in Glaucoma.

Use of Brij Lysis As a General Method to Prepare Polyribosomes from Escherichia Coli.

Brimonidine tartrate for the treatment of glaucoma

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment

Sustained release ocular drug delivery systems for glaucoma therapy

Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy

Active Trans-Corneal Drug Delivery with Ocular Adhesive Micelles for Efficient Glaucoma Therapy.

Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma

Anti-oxidative mesoporous polydopamine-based hypotensive nano-eyedrop for improved glaucoma management

Brimonidine as a possible treatment for myopia

Fabrication of Anti-glaucoma Nanofibers as Controlled-Release Inserts for Ophthalmic Delivery of Brimonidine Tartrate: In Vivo Evaluation in Caprine Eye

Nanoemulsion based In-situ Gel for ocular delivery of Brimonidine Tartrate

Micro-interaction of montmorillonite-loaded nanoparticles with mucin promotes retention of betaxolol hydrochloride on the ocular surface and the tear film microenvironment

Brinzolamide plus brimonidine for the treatment of glaucoma: an update

The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

A clinical multicenter comparative study of domestic and imported brimonidine in 139 patients

Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation

Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study